{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:45:41Z","timestamp":1790358341135,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) is an aggressive disease with grim prognosis due to lack of effective treatment options. Disease prediction in association with early diagnosis may both contribute to improved MPM survival. Inflammation and autophagy are two processes associated with asbestos-induced transformation. We evaluated the level of two autophagic factors ATG5 and HMGB1, microRNAs (miRNAs) such as miR-126 and miR-222, and the specific biomarker of MPM, soluble mesothelin related proteins (Mesothelin) in asbestos-exposed individuals, MPM patients, and healthy subjects. The performance of these markers in detecting MPM was investigated in pre-diagnostic samples of asbestos-subjects who developed MPM during the follow-up and compared for the three groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ATG5 best distinguished the asbestos-exposed subjects with and without MPM, while miR-126 and Mesothelin were found as a significant prognostic biomarker for MPM. ATG5 has been identified as an asbestos-related biomarker that can help to detect MPM with high sensitivity and specificity in pre-diagnostic samples for up to two years before diagnosis. To utilize this approach practically, higher number of cases has to be tested in order to give the combination of the two markers sufficient statistical power. Performance of the biomarkers should be confirmed by testing their combination in an independent cohort with pre-diagnostic samples.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-023-06330-1","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T10:02:09Z","timestamp":1682330529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["ATG5 as biomarker for early detection of malignant mesothelioma"],"prefix":"10.1186","volume":"16","author":[{"given":"Marco","family":"Tomasetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Strogovets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Volpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lory","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"6330_CR1","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/ijerph18052211","volume":"18","author":"JD Wortzel","year":"2021","unstructured":"Wortzel JD, Wiebe DJ, Elahi S, Agawu A, Barg FK, Emmett EA. Ascertainment Bias in a historic cohort study of residents in an asbestos Manufacturing Community. Int J Environ Res Public Health. 2021;18:2211. https:\/\/doi.org\/10.3390\/ijerph18052211.","journal-title":"Int J Environ Res Public Health"},{"key":"6330_CR2","doi-asserted-by":"publisher","unstructured":"van Kooten JP, Belderbos RA, von der Th\u00fcsen JH, Aarts MJ, Verhoef C, Burgers JA et al. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study.Thorax. 2022 thoraxjnl-2021-217709. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217709.","DOI":"10.1136\/thoraxjnl-2021-217709"},{"key":"6330_CR3","doi-asserted-by":"publisher","first-page":"e022806","DOI":"10.1136\/bmjopen-2018-022806","volume":"8","author":"RT Lin","year":"2018","unstructured":"Lin RT, Soeberg MJ, Chien LC, Fisher S, Takala J, Lemen R, et al. Bibliometric analysis of gaps in research on asbestos-related diseases: declining emphasis on public health over 26 years. BMJ Open. 2018;8:e022806. https:\/\/doi.org\/10.1136\/bmjopen-2018-022806.","journal-title":"BMJ Open"},{"key":"6330_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","volume":"167","author":"A Scherpereel","year":"2022","unstructured":"Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, et al. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022;167:8\u201316. https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.012.","journal-title":"Lung Cancer"},{"key":"6330_CR5","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.02.01","author":"G Gaudino","year":"2020","unstructured":"Gaudino G, Xue J, Yang H. How asbestos and other fibers cause mesothelioma. Transl Lung Cancer Res. 2020. https:\/\/doi.org\/10.21037\/tlcr.2020.02.01. S39-S46.","journal-title":"Transl Lung Cancer Res"},{"key":"6330_CR6","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1073\/pnas.0604008103","volume":"103","author":"H Yang","year":"2006","unstructured":"Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA. 2006;103:10397\u2013402. https:\/\/doi.org\/10.1073\/pnas.0604008103.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6330_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/pcm-21-12","volume":"4","author":"AA Zolondick","year":"2021","unstructured":"Zolondick AA, Gaudino G, Xue J, Pass HI, Carbone M, Yang H. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches - a narrative review. Precis Cancer Med. 2021;4:27. https:\/\/doi.org\/10.21037\/pcm-21-12.","journal-title":"Precis Cancer Med"},{"key":"6330_CR8","doi-asserted-by":"publisher","first-page":"25543","DOI":"10.1073\/pnas.2007622117","volume":"117","author":"J Xue","year":"2020","unstructured":"Xue J, Patergnani S, Giorgi C, Suarez J, Goto K, Bononi A, et al. Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proc Natl Acad Sci USA. 2020;117:25543\u201352. https:\/\/doi.org\/10.1073\/pnas.2007622117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6330_CR9","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","volume":"22","author":"A Napolitano","year":"2016","unstructured":"Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res. 2016;22:3087\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1130.","journal-title":"Clin Cancer Res"},{"key":"6330_CR10","doi-asserted-by":"publisher","first-page":"5756102","DOI":"10.1155\/2017\/5756102","volume":"2017","author":"S Ying","year":"2017","unstructured":"Ying S, Jiang Z, He X, Yu M, Chen R, Chen J, et al. Serum HMGB1 as a potential biomarker for patients with asbestos-related diseases. Dis Markers. 2017;2017:5756102. https:\/\/doi.org\/10.1155\/2017\/5756102.","journal-title":"Dis Markers"},{"key":"6330_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.21037\/jtd.2017.12.17","volume":"10","author":"R Foddis","year":"2018","unstructured":"Foddis R, Bonotti A, Landi S, Fallahi P, Guglielmi G, Cristaudo A. Biomarkers in the prevention and follow-up of workers exposed to asbestos. J Thorac Dis. 2018;10:360\u2013S368. https:\/\/doi.org\/10.21037\/jtd.2017.12.17.","journal-title":"J Thorac Dis"},{"key":"6330_CR12","doi-asserted-by":"publisher","first-page":"4183157","DOI":"10.1155\/2019\/4183157","volume":"2019","author":"Y Wang","year":"2019","unstructured":"Wang Y, Jiang Z, Yan J, Ying S. HMGB1 as a potential biomarker and therapeutic target for malignant mesothelioma. Dis Markers. 2019;2019:4183157. https:\/\/doi.org\/10.1155\/2019\/4183157.","journal-title":"Dis Markers"},{"key":"6330_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/1055-9965.EPI-18-0453","volume":"28","author":"L Santarelli","year":"2019","unstructured":"Santarelli L, Gaetani S, Monaco F, Bracci M, Valentino M, Amati M. Four-miRNA signature to identify asbestos-related lung malignancies. Cancer Epidemiol Biomarkers Prev. 2019;28:119\u201326. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0453.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"6330_CR14","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/s41598-017-02694-0","volume":"7","author":"C De Santi","year":"2017","unstructured":"De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci Rep. 2017;7(1):3140. https:\/\/doi.org\/10.1038\/s41598-017-02694-0.","journal-title":"Sci Rep"},{"key":"6330_CR15","doi-asserted-by":"publisher","first-page":"105700","DOI":"10.1016\/j.biocel.2020.105700","volume":"121","author":"S Gaetani","year":"2020","unstructured":"Gaetani S, Monaco F, Alessandrini F, Tagliabracci A, Sabbatini A, Bracci M, et al. Mechanism of miR-222 and miR-126 regulation and its role in asbestos-induced malignancy. Int J Biochem Cell Biol. 2020;121:105700. https:\/\/doi.org\/10.1016\/j.biocel.2020.105700.","journal-title":"Int J Biochem Cell Biol"},{"key":"6330_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/oemed-2015-102803","volume":"73","author":"D Ferrante","year":"2016","unstructured":"Ferrante D, Mirabelli D, Tunesi S, Terracini B, Magnani C. Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment. Occup Environ Med. 2016;73:147\u201353. https:\/\/doi.org\/10.1136\/oemed-2015-102803.","journal-title":"Occup Environ Med"},{"key":"6330_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clinbiochem.2012.02.009","volume":"45","author":"M Tomasetti","year":"2012","unstructured":"Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem. 2012;45:575\u201381. https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.02.009.","journal-title":"Clin Biochem"},{"key":"6330_CR18","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.21037\/jtd-21-555","volume":"13","author":"A Murrone","year":"2021","unstructured":"Murrone A, Cantini L, Pecci F, Cognigni V, Copparoni C, Rinaldi S, et al. BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma. J Thorac Dis. 2021;13:5741\u201351. https:\/\/doi.org\/10.21037\/jtd-21-555.","journal-title":"J Thorac Dis"},{"key":"6330_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","volume":"17","author":"A Louw","year":"2022","unstructured":"Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, et al. BAP1 loss by immunohistochemistry predicts improved survival to first line platinum\/pemetrexed chemotherapy for pleural mesothelioma patients: a validation study. J Thorac Oncol. 2022;17:921\u201330. https:\/\/doi.org\/10.1016\/j.jtho.2022.04.008.","journal-title":"J Thorac Oncol"},{"key":"6330_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.lungcan.2022.01.016","volume":"165","author":"L Cantini","year":"2022","unstructured":"Cantini L, Laniado I, Murthy V, Sterman D, Aerts JGJV. Immunotherapy for mesothelioma: moving beyond single immune check point inhibition. Lung Cancer. 2022;165:91\u2013101. https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.016.","journal-title":"Lung Cancer"},{"key":"6330_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.21037\/tlcr-19-686","volume":"9","author":"L Cantini","year":"2020","unstructured":"Cantini L, Belderbos RA, Gooijer CJ, Dumoulin DW, Cornelissen R, Baart S, et al. Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the dutch expanded access program. Transl Lung Cancer Res. 2020;9:1169\u201379. https:\/\/doi.org\/10.21037\/tlcr-19-686.","journal-title":"Transl Lung Cancer Res"},{"key":"6330_CR22","doi-asserted-by":"publisher","first-page":"e221490","DOI":"10.1001\/jamanetworkopen.2022.1490","volume":"5","author":"T Meirson","year":"2022","unstructured":"Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, et al. Comparison of 3 randomized clinical trials of Frontline Therapies for Malignant Pleural Mesothelioma. JAMA Netw Open. 2022;5:e221490. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.1490.","journal-title":"JAMA Netw Open"},{"key":"6330_CR23","doi-asserted-by":"publisher","unstructured":"Messori A, Trippoli S. J Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials. Chemother. 2022;1\u20135. https:\/\/doi.org\/10.1080\/1120009X.2022.2061183.","DOI":"10.1080\/1120009X.2022.2061183"},{"key":"6330_CR24","doi-asserted-by":"publisher","first-page":"100280","DOI":"10.1016\/j.jtocrr.2022.100280","volume":"3","author":"K Kerrigan","year":"2022","unstructured":"Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S. A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the Differential Impacts on overall survival by practice pattern. JTO Clin Res Rep. 2022;3:100280. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100280.","journal-title":"JTO Clin Res Rep"},{"key":"6330_CR25","doi-asserted-by":"publisher","first-page":"175883592211166","DOI":"10.1177\/17588359221116604","volume":"14","author":"L Yang","year":"2022","unstructured":"Yang L, Cao X, Li N, Zheng B, Liu M, Cai H. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol. 2022;14:17588359221116604. https:\/\/doi.org\/10.1177\/17588359221116604.","journal-title":"Ther Adv Med Oncol"},{"key":"6330_CR26","doi-asserted-by":"publisher","first-page":"947375","DOI":"10.3389\/fpubh.2022.947375","volume":"10","author":"ZM Ye","year":"2022","unstructured":"Ye ZM, Tang ZQ, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for american patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10:947375. https:\/\/doi.org\/10.3389\/fpubh.2022.947375.","journal-title":"Front Public Health"},{"key":"6330_CR27","doi-asserted-by":"crossref","unstructured":"Baas P, Daumont MJ, Lacoin L, Penrod JR, Carroll R, Venkatesan S et al. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013\u20132017: A nationwide CAS registry analysis from the I-O Optimise initiative. Lung Cancer. 2021;162:185\u2013193. doi:0.1016\/j.lungcan.2021.11.001.","DOI":"10.1016\/j.lungcan.2021.11.001"},{"key":"6330_CR28","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3389\/fimmu.2018.02334","volume":"9","author":"X Ye","year":"2018","unstructured":"Ye X, Zhou XJ, Zhang H. Exploring the role of autophagy-related gene 5 (ATG5) yields important insights into autophagy in autoimmune\/autoinflammatory diseases. Front Immunol. 2018;9:2334. https:\/\/doi.org\/10.3389\/fimmu.2018.02334.","journal-title":"Front Immunol"},{"key":"6330_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13104-019-4113-7","volume":"12","author":"DG Weber","year":"2019","unstructured":"Weber DG, Brik A, Casjens S, Burek K, Lehnert M, Pesch B, et al. Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study. BMC Res Notes. 2019;12:77. https:\/\/doi.org\/10.1186\/s13104-019-4113-7.","journal-title":"BMC Res Notes"},{"key":"6330_CR30","doi-asserted-by":"publisher","unstructured":"Pass HI, Alimi M, Carbone M, Yang H, Goparaju CM. Thorac Surg Clin Mesothelioma biomarkers: Discovery in search of validation. 2020;30:395\u2013423. https:\/\/doi.org\/10.1016\/j.thorsurg.2020.08.001.","DOI":"10.1016\/j.thorsurg.2020.08.001"},{"key":"6330_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/diagnostics11020356","volume":"11","author":"NA Handke","year":"2021","unstructured":"Handke NA, Rupp ABA, Trimpop N, von Pawel J, Holdenrieder S. Soluble high mobility group box 1 (HMGB1) is a promising biomarker for prediction of therapy response and prognosis in advanced lung cancer patients. Diagnostics (Basel). 2021;11:356. https:\/\/doi.org\/10.3390\/diagnostics11020356.","journal-title":"Diagnostics (Basel)"},{"key":"6330_CR32","doi-asserted-by":"publisher","first-page":"852812","DOI":"10.3389\/fcell.2022.852812","volume":"10","author":"L Heged\u00fcs","year":"2022","unstructured":"Heged\u00fcs L, Sz\u00fccs KD, Kudla M, Heidenreich J, Jendrossek V, Pe\u00f1a-Llopis S, et al. Nintedanib and dasatinib treatments induce protective autophagy as a potential resistance mechanism in MPM cells. Front Cell Dev Biol. 2022;10:852812. https:\/\/doi.org\/10.3389\/fcell.2022.852812.","journal-title":"Front Cell Dev Biol"},{"key":"6330_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41419-021-03668-x","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Liang SQ, Yang Z, Yang H, Bruggmann R, Oberhaensli S, et al. Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell Death Dis. 2021;12:406. https:\/\/doi.org\/10.1038\/s41419-021-03668-x.","journal-title":"Cell Death Dis"},{"key":"6330_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","volume":"90","author":"L Santarelli","year":"2015","unstructured":"Santarelli L, Staffolani S, Strafella E, Nocchi L, Manzella N, Grossi P, et al. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer. 2015;90:457\u201364. https:\/\/doi.org\/10.1016\/j.lungcan.2015.09.021.","journal-title":"Lung Cancer"},{"key":"6330_CR35","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1038\/s41598-018-32315-3","volume":"8","author":"G Johnen","year":"2018","unstructured":"Johnen G, Burek K, Raiko I, Wichert K, Pesch B, Weber DG, et al. MoMar Study Group. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers. Sci Rep. 2018;8:14321. https:\/\/doi.org\/10.1038\/s41598-018-32315-3.","journal-title":"Sci Rep"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-023-06330-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T10:03:14Z","timestamp":1682330594000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-023-06330-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6330"],"URL":"https:\/\/doi.org\/10.1186\/s13104-023-06330-1","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out according to the Helsinki Declaration and samples were processed under approval. Informed consent was obtained from all subjects. The entire study protocol was approved by the Ethical Committee of the University Hospital of Marche, N. 51\/DG 05\/02\/2009, Italy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}